In the second approval, the FDA has lifted the restriction to post-menopausal on use of Verzenio in advanced breast cancer, making it an option for all adults, including pre- and peri-menopausal ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress ...